Cabaletta: FDA Clearance of IND Application for Lupus

 IND application cleared within 6 months of in-licensing CABA-201 binder –

– CABA-201 data package and experience from prior autoimmune cell therapy INDs informed Phase 1/2 clinical trial design, including the initial dose to be evaluated and the patient dosing intervals –

https://finance.yahoo.com/news/cabaletta-bio-receives-fda-clearance-110000421.html